Postmenopausal hormone therapy increases use of health services: Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]

American Journal of Obstetrics and Gynecology

Volumn 195, Issue 1, 2006, Pages 62-71

  Veerus, Piret ^a,b,c   Fischer, Krista ^d   Hovi, Sirpa Liisa ^c,e   Hakama, Matti ^c   Rahu, Mati ^a,b   Hemminki, Elina ^e  

^a NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^b Estonian Centre of Excellence in Behavioural and Health Sciences   (Estonia)

^c UNIVERSITY OF TAMPERE   (Finland)

^d UNIVERSITY OF TARTU   (Estonia)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Health care costs; Postmenopausal hormone therapy; Utilization of health services

Indexed keywords

ESTROGEN; HORMONE; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG COST; ELECTROCARDIOGRAM; ELECTRONIC DATA INTERCHANGE; ESTONIA; FAMILY MEDICINE; FEMALE; FOLLOW UP; GYNECOLOGIC SURGERY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PRACTITIONER; HEALTH SERVICE; HORMONAL THERAPY; HUMAN; INFORMATION PROCESSING; NORMAL HUMAN; OUTPATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TRANSVAGINAL ECHOGRAPHY;

ESTONIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS;

EID: 33745230189     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2005.12.037     Document Type: Article

References (33)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 288 (2002) 321-333
2. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy. JAMA 291 (2004) 47-53
3. Daly E., Roche M., Barlow D., Grady A., McPherson K., and Vessey M. HRT: an analysis of benefits, risks and costs. Br Med Bull 48 (1992) 368-400
4. Samsioe G. The menopause revisited. Int J Gynaecol Obstet 51 (1995) 1-13
5. Townsend J., and Buxton M. Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy. Health Policy 39 (1997) 181-194
6. Cheung A.P., and Wren B.G. A cost-effectiveness analysis of hormone replacement therapy in the menopause. Med J Aust 156 (1992) 312-316
7. Daly E., Vessey M.P., Barlow D., Gray A., McPherson K., and Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 23 (1996) 247-259
8. Hurley J.S., Frost E.J., Trinkaus K.M., Buatti M.C., and Emmett K.E. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. Am J Manag Care 4 (1998) 1691-1698
9. Hoerger T.J., Downs K.E., Lakshmanan M.C., Lindrooth R.C., Plouffe Jr. L., Wendling B., et al. Healthcare use among U.S. women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Womens Health Gend Based Med 8 (1999) 1077-1089
10. Thorp J.M., Gavin N.I., and Ohsfeldt R.L. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users. Am J Obstet Gynecol 185 (2001) 318-326
11. Ohsfeldt R.L., Gavin N.I., and Thorp J.M. Medical care costs associated with postmenopausal estrogen plus progestogen therapy. Value Health 7 (2004) 544-553
12. Zethraeus N., Johannesson M., and Jonsson B. A computer model to analyse the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15 (1999) 352-365
13. Mullins C.D., and Ohsfeldt R.L. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 9 (2003) 150-158
14. Plumb J.M., and Guest J.F. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. Pharmacoeconomics 18 (2000) 477-486
15. Hemminki E., Hovi S.L., Veerus P., Sevon T., Tuimala R., Rahu M., et al. Blinding decreased recruitment in a prevention trial of postmenopausal hormone therapy. J Clin Epidemiol 57 (2004) 1237-1243
16. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
17. Wassertheil-Smoller S., Hendrix S.L., Limacher M., Heiss G., Kooperberg C., Baird A., et al. Effects of estrogen plus progestin on stroke in postmenopausal women-The Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
18. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women-The Women's Health Initiative randomized trial. JAMA 289 (2003) 3243-3253
19. Shumaker S., Legault C., Rapp S., Thal L., Wallace R., Ockene J., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women-The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
20. Cauley J.A., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density-The Women's Health Initiative Randomized Trial. JAMA 290 (2003) 1729-1738
21. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women-The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2663-2672
22. Hays J., Ockene J.K., Brunner R.L., Kotchen J.M., Manson J.E., Patterson R.E., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854
23. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures-The Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
24. Vorobjov S., Hovi S.L., Veerus P., Pisarev H., Rahu M., and Hemminki E. Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial. [ISRCTN35338757]. Maturitas 52 (2005) 286-295
25. Estonian Health Insurance Fund. Available at: http://www.haigekassa.ee/eng/ehif. Accessed on August 10, 2004.
26. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision (1992), World Health Organization, Geneva
27. Breslow N.E. Extra-Poisson variation in log-linear models. Applied Statistics 33 (1984) 38-44
28. The R Project for Statistical Computing. Available at: http://www.r-project.org. Accessed on January 3, 2005.
29. Drummond M., Torrance G., and Mason J. Cost-effectiveness league tables: more harm than good?. Soc Sci Med 37 (1993) 33-40
30. Coast J. Is economic evaluation in touch with society's health values?. BMJ 329 (2004) 1233-1236
31. Day S.J., and Altman D.G. Blinding in clinical trials and other studies. BMJ 321 (2000) 504
32. Hyland M.E. Using the placebo response in clinical practice. Clin Med 3 (2003) 347-350
33. Hovi S.L., Hakama M., Veerus P., Rahu M., and Hemminki E. Who wants to join into preventive trials-experience from the Estonian Postmenopausal Hormone Therapy trial. BMC Med Res Methodol 5 (2005) 12